IMR Press / EJGO / Volume 29 / Issue 3 / pii/1630995585429-1400905367

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Original Research
Whole-body positron emission tomography with 18Ffluorodeoxyglucose is an effective method to detect extra-pelvic recurrence in uterine sarcomas
P. L. Sung1,5Y. J. Chen1,5R. S. Liu2,5H. J. Shieh2,5P. H. Wang1,5M. S. Yen1,5K. C. Wen1,5 S. H. Shen3,5C. R. Lai4,5C. C. Yuan1,5,*
Show Less
1 Department of Obstetrics and Gynecology, Taipei Veterans General Hospital
2 Department of Nuclear Medicine, Taipei Veterans General Hospital
3 Department of Radiology, Taipei Veterans General Hospital
4 Department of Pathology, Taipei Veterans General Hospital
5 National Yang-Ming University (Taiwan)
Eur. J. Gynaecol. Oncol. 2008, 29(3), 246–251;
Published: 10 June 2008

Purpose of investigation: To assess the clinical use of F-18-fluorodeoxyglucose positron emission tomography (FDG-PET) in the post-therapy surveillance of uterine sarcoma. Methods: Eight whole-body FDG-PET studies were performed in seven women with previously treated uterine sarcoma. Conventional image studies (computed tomography) and physical examinations were performed for follow-up. All FDG-PET studies were indicated to localize suspected recurrences noted by conventional methods. Results: The per case sensitivity of the FDG-PET studies and CT scans was 85.7% (6/7) and 100% (7/7), respectively (p = 0.174). FDG-PET was able to detect seven extrapelvic metastastic sites below the diaphragm (7/7, sensitivity: 100%), including the liver, spleen, paraaortic lymph node, spine and paracolic gutter, as well as pulmonary lesions in five patients, while the CT scan detected only three lesions (3/7, sensitivity: 42.9%; p = 0.070). FDG-PET detected only four recurrent pelvic lesions (4/6) and CT scan detected six (6/6 ) recurrent pelvic lesions (66.7% vs 100%, p = 0.455). Conclusions: The FDG-PET showed a better detection rate than the abdominal CT scan for extrapelvic metastatic lesions and a similar detection rate as well as abdominal CT scan. FDG-PET can serve as a useful detection tool for patients with uterine sarcomas because nearly 80% of recurrence involve an extrapelvic site.
Recurrent uterine sarcoma
Post-treatment surveillance
Back to top